Nidogen-2: A new serum biomarker for ovarian cancer

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 355-361

  Kuk, Cynthia ^a,b   Gunawardana, C Geeth ^a,b   Soosaipillai, Antoninus ^c   Kobayashi, Hiroshi ^d   Li, Lin ^e   Zheng, Yingye ^e   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Basement membrane; Biomarker; Mass spectrometry; Nidogen 2; Ovarian cancer; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; ENTACTIN; NIDOGEN 2; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BASEMENT MEMBRANE; BENIGN TUMOR; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CELL ADHESION MOLECULES; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 76749172190     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.10.012     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. C.A. Cancer J. Clin. 58 (2008) 71-96
2. Bhoola S., and Hoskins W. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 107 (2006) 1399-1410
3. Jacobs I., and Bast R.J. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4 (1989) 1-12
4. Tuxen M., Soletormos G., and Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev. 21 (1995) 215-245
5. Bast R.J., and Knapp R. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 19 (1985) 354-356
6. Kuk C., Kulasingam V., Gunawardana C., Smith C., Batruch I., and Diamandis E. Mining the ovarian cacner ascites proteome for potential ovarian cancer biomarkers. Mol. Cell. Proteomics. 8 (2009) 661-669
7. Kulasingam V., and Diamandis E. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5 (2008) 588-599
8. Yurchenco P., Amenta P., and Patton B. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 22 (2004) 521-538
9. Adams J., and Watt F. Regulation of development and differentiation by the extracellular matrix. Development 117 (1993) 1183-1198
10. Ashkenas J., Muschler J., and Bissell M. The extracellular matrix in epithelial biology, shared molecules and common themes in distinct phyla. Dev. Biol. 17 (1996) 433-444
11. Dziadek M. Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Experientia 51 (1995) 901-913
12. Ekblom P., Ekblom M., Fecker L., et al. Role of mesenchymal nidogen for epithelial morphogenesis in vitro. Development 120 (1994) 2003-2014
13. Fox J.W., Mayer U., Nischt R., et al. Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. EMBO 10 (1991) 3137-3146
14. Kohfeldt E., Sasaki T., Gohring W., and Timpl R. Nidogen-2: a new basement membrane protein with diverse binding properties. J. Mol. Biol. 282 (1998) 99-109
15. Aumailley M., Wiedemann H., Mann K., and Timpl R. Binding of nidogen and the laminin-nidogen complex to basement membrane collagen type IV. Eur. J. Biochem. 184 (1989) 241-248
16. Mayer U., Nischt R., Poschl E., et al. A single EGF-link motif of laminin is responsible for high affinity nidogen binding. EMBO J. 12 (1993) 1879-1885
17. Timpl R., and Brown J. Supramolecular assembly of basement membranes. Bioassays 18 (1996) 123-132
18. Miosge N., Holzhausen S., Zelent C., Sprysch P., and Herken R. Nidogen-1 and nidogen-2 are found in basement membranes during human embryonic development. Histochem. J. 33 (2001) 523-530
19. Miosge N., Sasaki T., and Timpl R. Evidence of nidogen-2 compensation for nidogen-1 deficiency in transgenic mice. Matrix Biol. 21 (2002) 611-621
20. Dedhar S., Jewell K., Rojiani M., and Gray V. The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J. Biol. Chem. 267 (1992) 18908-18914
21. Dong L., Hsieh J., and Chung A. Two distinct cell attachment sites in entactin are revealed by amino acid substitutions and deletion of the RGD sequence in the cysteine-rich epidermal growth factor repeat 2. J. Biol. Chem. 270 (1995) 15838-15843
22. Wu C., Chung A., and Mcdonald J. A novel role for alpha 3 beta 1 integrins in extracellular matrix assembly. J. Cell. Sci. 108 (1995) 2511-2523
23. Yi X.Y., Wayner E., Kim Y., and Fish A. Adhesion of cultured human kidney mesangial cells to native entactin: role of integrin receptors. Cell. Adhes. Commun. 5 (1998) 237-248
24. Gadducci A., Baicchi U., Murrai R., Ferdeghini M., Bianchi R., and Facchini V. Preoperative evaluation of D-dimer and CA125 levels in differentiating benign from malignant ovarian masses. Gynecol. Oncol. 60 (1996) 197-202
25. Kim J., Skates S., Uede T., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287 (2002) 1671-1679
26. Mok S.C., Chao J., Skates S., et al. Prostatin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. 93 (2001) 1458-1464
27. Woolas R., Xu F.J., Jacobs I., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer Inst. 85 (1993) 1748-1751
28. Woolas R., Conaway M., Xu F., et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59 (1995) 111-116
29. Mills G., Bast R., and Srivastava S. Future for ovarian cancer screening: novel markers for emerging technologies of transcriptional profiling and proteomics. J. Natl. Cancer Inst. 93 (2001) 1437-1439
30. Sherwood D., Butler J., Kramer J., and Sternberg P. FOS-I promotes basement membrane removal during anchor-cell invasion in C. elegans. Cell 212 (2005) 951-962
31. Lester B., and Mccarthy J. Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis. Rev. 11 (1992) 31-44
32. Bassi D., Lopez De Cicco R., Cenna J., Litwin S., Cukierman E., and Klein-Szanto A.J. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res. 65 (2005) 7310-7319
33. Mueller M., and Fusenig N. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4 (2004) 839-849
34. Ulazzi L., Sabbioni S., Miotto E., et al. Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol. Cancer 28 (2007) 17-25